What is the maximum recommended dose of Cardizem (diltiazem) for rate control in atrial fibrillation with rapid ventricular response?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Dose of Diltiazem for Atrial Fibrillation with RVR

The maximum recommended dose of intravenous diltiazem for acute rate control in atrial fibrillation with rapid ventricular response is 15 mg/hour as a continuous infusion, with bolus dosing not to exceed 0.35 mg/kg (typically 25 mg for average-weight patients). 1

Initial Bolus Dosing

  • First bolus: Administer 0.25 mg/kg actual body weight IV over 2 minutes (20 mg is reasonable for average patients) 2, 1
  • Second bolus (if inadequate response after 15 minutes): Administer 0.35 mg/kg actual body weight IV over 2 minutes (25 mg is reasonable for average patients) 1
  • Onset of action occurs within 2-7 minutes after IV administration 2, 3

Continuous Infusion Maximum Dose

  • Initial infusion rate: Start at 10 mg/hour immediately following bolus administration 1
  • Some patients may maintain response at 5 mg/hour 1
  • Maximum infusion rate: 15 mg/hour 2, 1
  • The infusion may be increased in 5 mg/hour increments as needed for further heart rate reduction 1
  • Maximum duration: 24 hours 1
  • Critical limitation: Infusion rates exceeding 15 mg/hour and duration exceeding 24 hours have not been studied and are not recommended 1

Oral Maintenance Maximum Dose

  • Immediate-release: 120-360 mg daily in divided doses 2
  • Extended-release: 180-360 mg once daily 2, 3

Absolute Contraindications (Do Not Use Diltiazem)

  • Heart failure with reduced ejection fraction (LVEF ≤40%) 2, 3
  • Pre-excited atrial fibrillation (WPW syndrome with accessory pathway conduction) - may accelerate ventricular response and cause ventricular fibrillation 2, 3
  • Severe hypotension 3
  • Second or third-degree AV block without pacemaker 3
  • Decompensated heart failure 2

Critical Monitoring Parameters

  • Target heart rate: 60-80 bpm at rest or >20% reduction from baseline 2, 3
  • Monitor blood pressure continuously during administration 3
  • Watch for hypotension (occurs in 18-42% depending on dose) 3, 4
  • Monitor for bradycardia and heart block 3

Important Clinical Pearls

  • Lower doses may be equally effective with less hypotension: Research shows that doses ≤0.2 mg/kg achieve similar rate control (70.5% success) compared to standard doses (77.1% success) but with significantly lower hypotension rates (18% vs 34.9%) 4
  • Diltiazem carries a Class I recommendation with Level of Evidence B for acute rate control in atrial fibrillation 3
  • Avoid combining with beta-blockers due to risk of profound bradycardia from overlapping AV nodal blockade 2
  • In patients with heart failure, use digoxin or amiodarone instead 3
  • The half-life of IV diltiazem is 3-5 hours 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diltiazem Dosing for Rate Control in Atrial Fibrillation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Low-dose diltiazem in atrial fibrillation with rapid ventricular response.

The American journal of emergency medicine, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.